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Summary 
 
Type 2 diabetes (T2D) in adolescence manifests as a severe progressive form of diabetes that 
frequently presents with complications, responds poorly to treatment and results in rapid 
progression of microvascular and macrovascular complications. Whilst overall still a rare disease, 
adolescent T2D now poses major challenges to paediatric and adult diabetes services across many 
countries. Therapeutic options are heavily curtailed by a lack of knowledge about the condition, with 
low numbers and poor trial recruitment impeding research.  Together with lifestyle modification, 
metformin remains the first line therapy, although the majority rapidly progress to treatment failure 
and insulin therapy. Early bariatric surgery is controversial but has great potential to transform 
outcomes. Health systems must respond by both concentrating patients in specialist clinical services 
integrated with translational research programmes, but also joined-up with local health and social 
care services to improve engagement and take up of services.  
 
 
 
  
Introduction  
 
Type 2 diabetes (T2D) in adolescence is rapidly becoming one of the paradigmatic disorders of the 
twenty-first century. Historically T2D was a disorder of ageing, never seen in children or young 
people (CYP) outside of rare genetic variants. T2D is now well described in adolescents across the 
globe, resulting from the epidemiological transition from infectious diseases to non-communicable 
diseases (NCDs) and injuries, driven by changes in nutrition, sanitation and health related to rapid 
economic development and social change over the last decades of the twentieth century. 
Adolescent T2D is prototypical of the emerging burden of NCDs related to obesity risk, largely 
affecting high income countries but rapidly evolving across middle and even low income countries.  
 
The emergence of adolescent T2D presents new challenges for health systems. Adequately 
managing this new problem requires a paradigm shift for paediatric diabetes services and for the 
training of health professionals, hitherto almost entirely focused upon the much more common type 
1 diabetes (T1D) and dominated by technological advances (pumps, sensors) that are less relevant to 
T2D.  
 
In undertaking this seminar, we have focused on what is unique or particular to T2D in adolescence, 
using the World Health Organisation (WHO) definition of 10-19 years. Whilst young adults with T2D 
have also experienced a rapid rise in prevalence of T2D, and share many commonalitites with 
adolescents, we do not dwell on areas common to adult T2D.  
 
We searched the Cochrane Library and PubMed on 11 January 2017. We used the PubMed search 
terms (("Diabetes Mellitus, Type 2"[Mesh]) AND (("Child"[Mesh] OR "Adolescent"[Mesh])) and 
similar terms in the Cochrane Library, restricting our search to the past 5 years. Review articles are 
cited to provide readers with further detail and references. 
 
Aetiology and phenotype 
 
Adolescent T2D is likely to be caused by a similar range of defective pathways proposed in adult T2D 
including β cell failure, insulin resistance in liver and changes in incretin and pancreatic -cell 
function, kidney glucose filtration and lipolysis.1  There is evidence of exaggerated insulin 
insensitivity and rapid deterioration in β cell function in adolescent T2D. 2 3 Adolescents have severe 
insulin insensitivity, but show a greater loss of glucose-stimulated insulin secretion, with a 2 to 4 fold 
faster decline in β cell function than seen in adults. 2 Estimates suggest that β cell function may 
decline up to 20-35% per year on average, 3 with little change in insulin insensitivity over the same 
period. This rapid progression of β cell dysfunction likely explains the faster time to failure of 
metformin monotherapy in adolescents4 compared with adults.  The frequent emergence of T2D 
during puberty likely reflects the transient 25-30% reducing in insulin sensitivity during puberty.5 The 
increased frequency of T2D during puberty likely reflects the transient 25-30% reduction in insulin 
sensitivity during puberty.5 Obesity is near universal in adolescents with T2D6,7 and increases risk for 
T2D earlier in life.8  
 
Our knowledge of risk factors has been dramatically expanded by recent large cohort studies from 
North America. The TODAY cohort9 was 65% female, ethnically highly diverse (largely from non-
white groups: 41.1% Hispanic, 31.5% non Hispanic black) and predominantly from financially 
deprived backgrounds. Similar characteristics were observed in the Pediatric Diabetes Consortium 
(PDC) from 8 US academic centres,7,10 a population-based Canadian cohort6 and a national study 
across England and Wales11 (see Figure 1).  
 
Positive family histories of diabetes are nearly 90% within the first or second generation.9 Genetic 
studies of T2D have been confined to adults, however it is likely that similar genetic factors also 
operate in adolescents.12 Risk related to ethnicity is likely to represent genetic issues including 
metabolic differences as well as a range of complex cultural and social factors including 
deprivation.11 
 
One-third of adolescents with T2D are born to mothers with GDM9 and are diagnosed at a younger 
age and with poorer B-cell function and higher HbA1c.13 It is likely that this reflects shared 
environments and genetic predisposition. 
 
Observational epidemiology has identified a number of other potential risk factors: 
 Those born at low birthweight and with rapid weight gain in childhood appear most at risk for 
T2D in young adult and adult life.14,15  
 The very strong association of adolescent T2D with low socio-demographic status is likely 
mediated partly through the association of deprivation with obesity, but also through stress and 
its concomitant mental health disorders such as depression, which increase T2D risk.16,17 
 A recent systematic review concluded that antipsychotic-exposed youth had a cumulative T2D 
risk of 5.7 per 1000 patients, many-fold higher than the general population and in psychiatric 
controls.18 Risk relates to rapid weight gain but may also relate to effects on insulin sensitivity 
and the hypothalamus.19 Atypical antipsychotic prescribing to children and adolescents 
increased 60-fold in the UK from the mid1990s to reach 0.61 users per 1000 patient-years in 
2005.20 
 
Epidemiology 
 
The extent of the burden of T2D in adolescence remains unclear. The only recent national 
prevalence rates are available from the UK (2.9/100,000 for under 16 year olds)11and from Denmark, 
where a register study identified only 7 adolescents nationally with T2D.21 In Europe, T2D meets 
criteria for being a rare disease (prevalence <5/10,000). 
 
Variation in incidence and prevalence across countries is striking. A systematic review reported an 
incidence range of 0–330 per 100,000 person-years and prevalence ranging from 0–5,300 per 
100,000 adolescents, although many studies were from limited samples and single ethnic groups.22 
The highest prevalence estimates were in Pima Indian and First Nation groups in North America.22  
 
The lowest incidence rates were observed in European countries, over ten-fold lower than in the 
USA. The most recent national paediatric diabetes audit in England and Wales identified 533 
adolescents with T2D, making up approximately 2% of all child and adolescent diabetes.23  
 
Longitudinal sub-national US data suggest that prevalence increased significantly by 7% annually 
during the twenty-first century, reaching 12.5 cases per 100,000 in 2011–12, with annual increases 
higher amongst black, Asians or Pacific Islanders, and Native Americans.24 T2D is reported to account 
for 10-50% of new onset adolescent diabetes cases in the USA,25,26 and over half amongst minority 
ethnic groups.27  
 
Few data are available outside the USA and Europe. Incidence of adolescent T2D doubled in two 
Korean regions between 2001 and 2010.28 Isolated reports from Asia suggest a rising prevalence of 
early onset T2D,29 with around 2-3% of T2D with onset under 20 years in south and east Asia30 and 
the Arab world.31  
 
Diagnosis and differentiation from other forms of diabetes  
 
The standard diagnostic criteria for diabetes are relevant for all forms of diabetes in adolescence, 
and are now based largely upon HbA1c values following a report from an International Expert 
Committee.32 These recommendations are based solely on evidence from adults which 
demonstrates a good correlation between HbA1c and diabetes-related complications. Screening 
using HbA1c, random- and fasting-glucose levels detect different populations33 34 leading to calls for 
a “mixed testing” approach using a combination of these measures in adolescents (an approach 
which the Expert Committee argued against). The International Society of Paediatric & Adolescent 
Diabetes (ISPAD) and ADA guidelines recommend screening using either fasting-, random-, 2-hour 
post-challenge glucose or HbA1c: 35 36 
 
 Random-, fasting-, and 2 hour post-challenge glucose thresholds remain unchanged. 
Diabetes should not be diagnosed solely on a random plasma glucose concentration >11.1 
mmol/l (>200 mg/dl) without classical symptoms of diabetes. 
 The diagnosis of diabetes is made if the HbA1C level is ≥6.5% (48 mmol/mol). ADA 
recommend a raised HbA1c should be confirmed with a second HbA1C test. 36 Further, they 
consider an HbA1c between 5.7% and 6.5% to represent a prediabetic state.  
 
The presumptive diagnosis related to persistent hyperglycaemia and its symptoms (e.g. thirst, 
polyuria, weight-loss and fatigue) in adolescents should be T1D, unless there are strong indications 
for other forms of diabetes.37 However, T2D should be considered in all incident cases, particularly 
when the clinical picture is unusual or there are features consistent with T2D. The classic features of 
T2D in adolescence are obesity, evidence of insulin resistance (e.g. acanthosis nigricans, seen in 86% 
in the TODAY cohort9), lack of auto-antibodies and a strong family history of T2D with ethnic 
minority groups most at risk (see Figure 1). 38 
 
Severe acute presentations of T2D are uncommon. Only 67% present with symptoms of diabetes 
with one third identified through screening of at-risk adolescents.10 Acute symptoms at presentation 
are rarely those of diabetic ketoacidosis (DKA), found in only 639 to 11%10 of incident cases. Reports 
that DKA is an increasing presentation amongst adolescent T2D appear misplaced, as the prevalence 
appears to have halved over the past 10-15 years.39 
 
Presentation with diabetic hyperglycaemic hyperosmolar syndrome (HHS; see Figure 2) is rare (e.g. 
2%),10 with most adolescent cases due to T1D.40 
 
Differentiation of T1D and T2D can be difficult in overweight young people who present with 
hyperglycaemia without ketosis. Modern adolescents with autoimmune T1DM may also be 
overweight or obese at diagnosis, and the commonality of adult T2D means that a positive family 
history is often seen in T1D. Pre-pubertal adolescents are unlikely to have T2D even if obese.35 The 
presence of diabetes complications at presentation is relatively common in T2D although very rare in 
T1D, and likely reflects long periods of asymptomatic hyperglycaemia before diagnosis. 
Differentiation of T2D from maturity-onset diabetes of the young (MODY) can be difficult in obese 
antibody-negative adolescents,41 and genetic testing should be performed if the phenotype is 
unclear (see Figure 3).  The presence of diabetes-specific autoantibodies at diagnosis is strongly 
suggestive of T1D, however 10% or more of those diagnosed with T2D can have autoantibodies, 
leading to uncertainty about the diagnosis.9 C-peptide is of little value at presentation although may 
be of value some months later if there is difficulty in finalising the diagnosis in those on insulin.42  
 
Complications and comorbidities 
 
Our understanding of the disease process in adolescents and the few data available suggest that the 
nature of complications are similar to those seen in adult T2D and in T1D. However the overall risk of 
complications is much higher than in T1D adolescents, with complications appearing earlier in the 
disease process.6 Longitudinal Canadian data suggest that macrovascular peripheral vascular 
complications began to occur 15 years after diagnosis in adolescent T2D.6 Adult cardiovascular risk 
tools are not informative for risk in adolescents with T2D. 
 
Renal disease is the commonest and earliest complication of adolescent T2D, with a higher risk of 
progression than in childhood T1D or adult T2D.43 The prevalence of microalbuminuria (MA) has 
recently been reported to be 13%9 to 27.1%6 at diagnosis and 16%44 to 38.6%6 after 4-5 years, with 
progression associated with HbA1c.44 Concerningly, data from the TODAY trial suggested that that 
MA progressed over time regardless of treatment arm.44 Hypertension has been reported in 106 to 
12%44 at diagnosis, increasing to 34%44, 36%45 to 45.8%6 after 4-5 years, with those with higher BMI 
at greater risk.44 
 
Little is known about the natural history of retinopathy in adolescent T2D, although there is some 
suggestion that progression is more rapid than in T1D. The largest and most representative cohort 
(TODAY) reported the prevalence of retinopathy was 13.7% after a mean duration of 5 years,46 
although the much smaller SEARCH cohort reported 42% with retinopathy after an average of 7 
years duration.47 Where identified, retinopathy was of low grade. Longer duration of diabetes and 
higher HbA1c predicted higher risk of retinopathy.46 One report identified a 6% prevalence of 
cataracts.48  
 
Dyslipidaemia, is the most prevalent and non-treatment responsive comorbidity of adolescent T2D. 
In the TODAY cohort at diagnosis using standard adult definitions of dyslipidaemia, 80.5% had low 
HDL-cholesterol, 10.2% had high triglycerides and 4.5% had significantly high LDL-cholesterol.9  Using 
definitions minimally altered for adolescents in the SEARCH cohort, 65.6% had high triglycerides and 
61.5% had low HDL-cholesterol after 2 years of T2D.49 TODAY reported that LDL rose across the 
cohort in line with HbA1c regardless of treatment, with the proportion having elevated LDL rising to 
10.7% after 3 years.44  
 
Data on neuropathy in adolescent T2D are extremely limited.  A prevalence of 7.6% after 6-7 years 
of diabetes6 was reported in a state-wide Canadian cohort. 
 
Adolescents with T2D have extremely poor pregnancy outcomes, with high rates of fetal loss (22%), 
preterm birth (15%) and major congenital anomalies (21%) in some cohorts.50 It remains unclear 
how much of these poor outcomes relate to the morbid obesity and deprivation associated with 
T2D.  
 
The prevalence of significant depressive symptoms in adolescents with T2D is 1544 to 22%,51 nearly 
twice as high as in T1D adolescents.51 Whilst females are most at risk, there is little evidence that 
BMI or deprivation increase risk.44 Depressed mood is associated with poorer glycaemic control, a 
greater number of visits to the emergency department and poor adherence to treatment 
recommendations.52 Exposure to major stressful life events is also associated with impaired 
psychosocial functioning and lower adherence to oral medication regimens in adolescents with 
recent onset T2D.53  
 
Neuropsychiatric comorbidity is also common in adolescent T2D, with one large cohort reporting the 
combined prevalence of depression, ADHD, neurodevelopmental disorders, schizophrenia and 
bipolar disorder in 19.4% of a sample of 237 adolescents with T2D, with 63% of those diagnosed on 
psychotropic medications.54 Clinically significant levels of binge eating have been reported in 6.2% of 
adolescents with T2D, with risk of binge eating associated with higher BMI.44 
 
QOL appears lower in adolescents with T2D than those with T1D,55 with higher BMI and a greater 
number of comorbidities linked with lower QOL.56 However it remains unclear to what degree 
reduced QOL relates to T2D or to obesity, deprivation or depression, which are themselves 
associated with reduced QOL.  
 
Adolescents with T2D show a wide range of emotional adjustment and levels of motivation for self-
care. Young people describe the need for support for diabetes specific behaviours and difficulty 
balancing competing interests. A consistent theme is a fear of disclosing their diagnosis to others. 
Parents report that the need for perceived normalcy is also factor in adjustment to T2D, and that 
adolescents with T2D have less problem-solving and coping skills; making sensible food choices is a 
common challenge.57 Witnessing negative health consequences in family members or friends with 
T2D can be an important source of motivation,58,59 but also a source of hopelessness.  
 
Management 
 
Core management should include intensive lifestyle modification comprising promotion of weight 
control through increased lifestyle activity, reduced sedentary behaviour and a healthy balanced diet 
with elimination if possible of simple sugars and reduced carbohydrate and total and saturated fat 
intake and increased fibre intake.35 Regular physical activity (PA) improves cardiorespiratory fitness, 
body composition, bone health, insulin sensitivity, and psychosocial well-being. However most 
adolescents with T2D do not meet recommended PA thresholds of 60 minutes of moderate exercise 
daily.60 
 
Observational data shows that some can achieve and sustain glycaemic control through lifestyle 
change alone;61,62 however lifestyle change has not been compared to drug therapy alone in 
randomised trials. A further assumption has been that lifestyle change combined with drug therapy 
improves glycaemic control; however the lifestyle programme used in TODAY did not enable 
improved glycaemic control.4  
 
Home management should include regular self-monitoring of capillary blood glucose (BG) in those 
on oral hypoglycaemic medications or insulin, although the necessary frequency when on oral 
medications is unclear.60  
 
Care should be provided by a multi-disciplinary team, with psychologists, dietitians and potentially 
physical therapists as core members of the team alongside specialist doctors and nurses.  
 
ISPAD suggests screening for all potential complications at diagnosis, including for obstructive sleep 
apnea (OSA), non-alcoholic related fatty liver disease (NAFLD) and depression as well as for 
pregnancy.35 Thereafter ISPAD suggests monitoring of HbA1c and blood pressure at each visit and 
annual monitoring of retinopathy, microalbuminuria, dyslipidaemia and liver function, with 
screening for OSA and depression less frequently. Smoking and other substance use should be part 
of annual screening.35 
 
Treatment of T2D is challenging for three main reasons. First, T2D is likely to be an umbrella of 
diseases, with different genetic, environmental and metabolic triggers that are likely not to respond 
equally to treatments.2 63 Furthermore, better understanding of drug action has shown individual 
pharmaco-genetic responses to drugs, including differing side-effect profiles for metformin 64  and 
pharmacodynamics of sulphonylureas. 65   
 
Second, there are few evidence-based treatments available due to lack of studies in this age group. 
The TODAY study is the only RCT to date examining different treatment options in adolescents.66 It 
compared metformin alone, metformin plus intensive lifestyle treatment and metformin plus 
rosiglitazone with baseline criteria including HbA1c <8% with metformin monotherapy. Metformin 
monotherapy resulted in treatment failure (defined as HbA1c >8%)  in half the group (51.7% of 
cohort) with those allocated to additionally receive the TDZ rosiglitazone having reduced likelihood 
of treatment failure (38.6%) but not those with an additional weight-loss intensive lifestyle 
programme (46.6%).66  
 
Metformin and insulin are currently the only drugs licenced for use in adolescent T2D. Guidelines 
from the American Diabetic Association (ADA), ISPAD and NICE each recommend metformin as first 
line treatment once initial metabolic derangement has resolved.36 42 35 The TODAY run-in period 
regimen of metformin monotherapy, together with expert education and support showed that 
glycaemic control can be improved with this triad. At the same time, 24% of this run-in group were 
not eligible for the main study due to inadequate adherence (10.9%), inability to achieve glycaemic 
control (6.3%), need for polypharmacy (2.5%) and metformin intolerance (2.0%). 67 Further 
treatments beyond metformin are needed.  
 
ADA and ISPAD but not NICE recommend insulin as the only second line treatment, with first line use 
to reverse the initial metabolic derangement in those who present with ketosis. US guidelines 
suggest insulin initiation when HbA1c is ≥9%.35 This is despite insulin's cost, associated weight gain, 
injectable formulation68, risk of hypoglycaemia and lack of evidence in this age group. In comparison, 
many drugs are licenced for use in adults in the USA and Europe, including biguanides (metformin), 
sulfonlyureas (SU), thiazolidinediones (TDZ), GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 
inhibitors, and insulins,36 although a number of these have failed to be licensed for adolescents.69 
 
Recent data from the PDC cohort suggests over 90% of adolescent T2D were treated with insulin or 
metformin, with approximately 30% on each of metformin or insulin alone and one-third on both, 
with only 7% on diet/lifestyle alone.10 Yet the proportions on insulin rise with each duration year, 
reaching 60% in those with T2D for ≥4 years.70 
 
Bariatric surgery is the only treatment currently available that results in significant weight loss and 
improved long term glycaemic control as well as improvements in blood pressure, lipids and sleep 
apnoea.71 72 Bariatric surgery is now an accepted treatment for T2D in adults, although there is 
insufficient evidence to recommend it as a mainline treatment for adolescent T2D.73 In the largest 
US adolescent cohort, 19 of 20 with T2D were in remission 3 years after surgery. 74  Of the three 
procedures widely used, the Roux-en-Y gastric bypass (GB) appears the most effective and most 
complex procedure. 71 Its complexity is likely to drive its superior efficacy in that it influences more 
pathways that have been suggested (but not definitely proven) to promote weight loss including gut 
microbiota changes, bile acid and incretin metabolism and vagal nerve changes.75 The ADA, ISPAD 
and NICE are cautious in recommending bariatric surgery in adolescence given limited evidence and 
hypothesised risks including reduced bone mineral density.71,76 77 However, the magnitude of weight 
loss is incomparable with other interventions with good safety data 74 making bariatric surgery a 
feasible option that should be encouraged in those with severe obesity and poorly controlled 
diabetes. Limited qualitative evidence suggests adolescents support surgery as a therapeutic 
option.68 
 
Many patients, families and clinicians are reluctant to initiate insulin or undergo surgery. 68 Clearly 
alternative treatment options are needed, and to this effect, ISPAD guidelines outline off-licence 
treatment options including DDP-IV antagonist and weight-beneficial GLP-1 agonists that both act on 
the incretin pathway  to increase satiety and improve glycaemic control. GLP-1 agonists have similar 
tolerability, safety,78 and pharmacokinetics79 as in adults, although their place in treatment pathways 
for adolescents is yet to be established.  
 
Blood pressure and lipid control are likely to be important to promote long term cardiovascular 
health. In the absence of robust evidence in this age group or expert consensus, clinicians should 
seek specialist guidance on treatment when age-appropriate thresholds for blood pressure or lipids 
are exceeded. Practice studies show lower concordance with BP and lipid than glucose 
recommendations, with lack of clinician familiarity a key barrier.80 This supports managing 
adolescent T2D in more specialist centres.  
 
Lastly, T2D is associated with high familial disease burden (especially type 2 diabetes), socio-
economic deprivation and multiple co-morbidities including obesity.9 A small clinical study found 
that clinic attendance by adolescents with T2D was notably lower than desired by professionals and 
very poor attenders had the highest HbA1c.81 Lifestyle change is likely to be an important 
component of diabetes treatment however these conflicting needs likely make change difficult.  The 
limited efficacy of lifestyle interventions in obesity likely reflects the complex interactions that 
influence behaviour, and broader interventions are likely to be needed including those at public 
health level.  
 
Prevention strategies 
 
Adequate management of adolescent T2D requires us to focus upstream from the individual young 
person to families and social systems and to the prevention of obesity. A discussion of preventive 
approaches to child and adolescent obesity is beyond the scope of this review, although there is 
emerging evidence that systemic approaches can halt or even reverse the rise of childhood obesity.  
 
There is very limited evidence on limiting progression of prediabetes or T2D. A recent systematic 
review identified a range of community, school or clinical interventions which improved various risk 
factors (e.g. dietary or physical activity measures) and indices of cardiometabolic health and may 
contribute to prevention of T2D,82 although currently no studies have shown efficacy in prevention 
of incidence of T2D.  
 
There is currently no evidence to support screening of obese adolescents for T2D.21 The vast 
majority of obese adolescents do not have T2D83 and do not develop it within adolescence  
 
Conclusion 
Adolescent T2D manifests with a severe and progressive phenotype, poor response to current 
treatments and major challenges in adherence and management.  
 
Increases in prevalence driven by the obesity epidemic are likely to pose major challenges for future 
burden of disease. Adolescent T2D in adolescence is theoretically preventable in the current state of 
knowledge, unlike T1D. Yet targeted prevention efforts have yielded little benefit, and success will 
likely depend on broader systemic efforts to reduce obesity.  
 
A major barrier to effective management is the lack of approved pharmacological agents and the 
lack of psychosocial or educational interventions of proven effectiveness. In common with other rare 
diseases this in part relates to poor visibility of the problem and the lack of patient numbers even in 
large centres. Added to this is also low participation in research trials.84 Even large national cohorts 
including the T2D in Childhood: UK National Cohort Study (JUMP study) in the UK,85 suffer from 
similar recruitment issues.  
 
We believe that adolescent T2D needs to be reframed as a severe progressive disorder, and 
adolescents with T2D recognised as a high risk group within both paediatric diabetes services and 
adult diabetes services, requiring innovative psychological and pharmacological approaches. 
Conceptualising T2D as a 'rare disease' may have benefits, highlighting its severity and the lack of 
service focus and available treatments for the condition. Rare diseases approaches therefore logical, 
concentrating patients in evidence-based specialist paediatric diabetes services that are integrated 
with world-class research with a focus on rapid translation of research findings into care and which 
are linked with adult diabetes services. Such services must actively work to share care with local 
services and primary care, potentially using novel telehealth technologies, although these are yet to 
be well-evidenced, to ensure integration of the health and social care systems around these 
vulnerable patients. Key research priorities include evaluation of safety, acceptability and 
effectiveness of newer pharmacological agents and combinations of agents, development of 
strategies for comorbidity management and cardiovascular risk minimization, interventions to 
promote adherence with regimens and facilitation of lifestyle change to enable weight loss and 
optimal methods of service delivery for this vulnerable group. 
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